Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 260

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma

Open access
Iyer, Jayasri G., Blom, Astrid, Doumani, Ryan, Lewis, Christopher, Tarabadkar, Erica S., Anderson, Austin, Ma, Christine, Bestick, Amy, Parvathaneni, Upendra, Bhatia, Shailender, Nghiem, Paul·2016·Cancer Medicine

Abstract

Cytotoxic chemotherapy is commonly used to treat advanced Merkel cell carcinoma (MCC). However, its efficacy in distant metastatic MCC patients is unclear, in part because most prior reports aggregated these patients with those receiving adjuvant chemotherapy and combined chemoradiation for whom prognosis and outcomes may differ. In this retrospective study, we analyzed detailed records from 62 patients with distant metastatic MCC treated with cytotoxic chemotherapy. Efficacy outcomes including response rate (RR), durability of response (DOR), progression‐free survival (PFS), and overall survival (OS) were evaluated. In this cohort, platinum plus etoposide was the most commonly used first‐line regimen (69%). RR to first‐line chemotherapy was 55% (34/62) with complete responses (CR) in 13% (8/62) and partial responses (PR) in 42% (26/62) while 6% (4/62) had stable disease and 39% (24/62) had progressive disease. Median PFS was 94 days and median OS was 9.5 months from start of chemotherapy. Among responding patients (n = 34), median PFS was 168 days and median DOR was 85 days. Among 30 of the 62 patients who received second‐line chemotherapy, RR was 23% (7/30; 1 CR, 6 PR), median PFS was 61 days, and median DOR was 101 days. In summary, first‐line chemotherapy is associated with a high RR in metastatic MCC, but responses are typically not durable, and the median PFS is only 3 months. These results suggest rapid emergence of chemoresistance in MCC tumors, and may serve as a useful comparator for immunotherapies currently being explored for metastatic MCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cam4.815

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 260

Metadata

Authors
Iyer, J. G., Blom, A., Doumani, R., Lewis, C., Tarabadkar, E. S., Anderson, A., Ma, C., Bestick, A., Parvathaneni, U., Bhatia, S., & Nghiem, P.
Venue
Cancer Medicine
Publisher
Wiley
Published
2016-07-19
Volume
5
Issue
9
Pages
2294-2301
ISSN
2045-7634 (ISSN-L)
OpenAlex
W2498543837
Cited by
260
References
2
FWCI
15.61
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. https://app.cochat.ai/papers/10.1002/cam4.815
The paper
Iyer, J. G., Blom, A., Doumani, R., Lewis, C., Tarabadkar, E. S., Anderson, A., Ma, C., Bestick, A., Parvathaneni, U., Bhatia, S., & Nghiem, P. (2016). Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.815

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.